Key Market Drivers, Trends, and Forecast for the Global Gene-Editing Transfection Chemicals Industry
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Gene-Editing Transfection Chemicals Market From 2025 to 2029?
The size of the gene-editing transfection chemicals market has seen significant growth in recent times. It is set to expand from $0.99 billion in 2024 to $1.07 billion in 2025, recording a compound annual growth rate (CAGR) of 8.0%. The historical growth can be ascribed to early implementation of CRISPR-Cas9 systems, increased concentration on research about cancer and genetic disorders, preliminary demand stemming from academic and research bodies, access to elementary chemical transfection reagents, along with the swift expansion of cell biology and molecular diagnostics.
Over the coming years, the market size for gene-editing transfection chemicals is predicted to experience substantial growth, expanding to $1.45 billion in 2029 with a compound annual growth rate (CAGR) of 7.8%. This anticipated growth in the forecast period is ascribed to numerous factors such as the heightened application of gene editing in clinical therapies, increased investment in the biotech and pharma sectors, a surge in demand for non-viral delivery systems, a rise in occurrences of rare and inherited diseases, a global advancement towards personalized medicine, and the growing landscape of regenerative treatments. Key trends for the forecast period include a transition towards nanoparticle and lipid-based delivery, the implementation of automation and high-throughput platforms, the introduction of microfluidic and single-cell delivery systems, the incorporation of nanotechnology, and the evolution of core-shell silica nanoparticle systems.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25770&type=smp
What Elements Are Contributing To Growth In The Gene-Editing Transfection Chemicals Market?
The swift progression in gene therapy research is anticipated to drive the expansion of the gene-editing transfection chemicals market. Gene therapy, a method that endeavors to cure or avert diseases by directly amending or rectifying malformed genes within an individual’s cells, is currently experiencing a boost. This is thanks to advances in gene-editing technologies like CRISPR, which facilitates scientists to accurately pinpoint and modify defective genes accountable for genetic disorders. Gene-editing transfection chemicals, which serve as critical instruments in gene therapy research and development, empower the effectual delivery of genetic elements like CRISPR-Cas9 components, mRNA, and plasmid DNA into human cells. For example, as reported by PartnerRe, a Switzerland-based insurance firm, by the close of 2023, the FDA endorsed 7 gene therapies, and 2024 is set to establish a new milestone with an additional seven approvals in the first half of the year alone. Presently, over 500 gene therapies are under development, and between 10 to 20 more gene and cell therapies are projected to gain FDA approval by 2025. As such, the swift advancement in gene therapy research is fueling the expansion of the gene-editing transfection chemicals market.
Which Segments Are Detailed In The Global Gene-Editing Transfection Chemicals Market Report?
The gene-editing transfection chemicals market covered in this report is segmented –
1) By Chemical Type: Lipid-Based, Polymer-Based, Peptide-Based, Other Chemical Types
2) By Delivery Mechanism: Non-Viral, Viral
3) By Application: Biomedical Research, Drug Discovery, Disease Modeling, Agricultural Biotechnology, Vaccine Development, Other Applications
4) By End-User: Academic And Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Lipid-Based: Cationic Lipids, Neutral Lipids, Ionizable Lipids
2) By Polymer-Based: Polyethyleneimine (PEI), Poly(L-Lysine) (PLL), Dendrimers
3) By Peptide-Based: Cell-Penetrating Peptides (CPPs), Amphipathic Peptides, Targeting Peptides
4) By Other Chemical Types: Inorganic Nanoparticles, Hybrid Nanoparticles
Which Emerging Trends And Strategic Shifts Are Shaping The Gene-Editing Transfection Chemicals Market?
Companies in the forefront of the gene-editing transfection chemicals market are geared towards launching cutting-edge solutions like lipid nanoparticle (LNP) starter kits to simplify gene therapy and mRNA delivery processes. The lipid nanoparticle (LNP) starter kits come as pre-packed formulations or comprehensive toolkits packed with optimised lipid elements and procedures constructed to ease the creation and evaluation of LNP-driven delivery systems. For instance, in February 2024, CordenPharma, a pharmaceutical firm based in Switzerland, rolled out Lipid NanoParticle (LNP) Starter Kits. The primary purpose of these kits is to assist researchers and video game developers in formulating and improving mRNA-based treatments, such as vaccines and gene therapies. The kits comprise four main lipids like ionisable lipids, helper lipids, sterols, and PEGylated lipids. These have been sourced from commercial-scale, high-purity materials to ascertain consistency between batches and minimise potential loss of high valued payloads during the developmental stages. By introducing a dependable, scalable lipid platform, CordenPharma is committed to expediting gene-editing and mRNA therapeutic development, whilst protecting high-value genetic payloads.
Who Are The Key Contributors To Growth In The Gene-Editing Transfection Chemicals Market?
Major companies operating in the gene-editing transfection chemicals market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, Integrated DNA Technologies Inc., Promega Corporation, Eurogentec S.A., Horizon Discovery Group plc, OriGene Technologies Inc., Enzo Life Sciences Inc., Apollo Scientific Ltd., Mirus Bio LLC, OZ Biosciences SAS, Genlantis Inc., Polyplus-Transfection SA, Altogen Biosystems LLC, Canvax Biotech S.L., EZ Biosystems LLC, SignaGen Laboratories.
Get The Full Report Here:
Which Region Is Projected To Lead The Gene-Editing Transfection Chemicals Market By 2025?
North America was the largest region in the gene-editing transfection chemicals market in 2024. The regions covered in the gene-editing transfection chemicals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25770&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
